Healthcare - Biotechnology - NASDAQ - IL
$ 0.4755
4.69 %
$ 39.8 M
Market Cap
-1.03
P/E
CASH FLOW STATEMENT
-22.6 M
OPERATING CASH FLOW
1.44 M
INVESTING CASH FLOW
15.1 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
BioLineRx Ltd.
| Net Income | -60.6 M |
| Depreciation & Amortization | 1.38 M |
| Capital Expenditures | -297 K |
| Stock-Based Compensation | 2.32 M |
| Change in Working Capital | 15.2 M |
| Others | 34.9 M |
| Free Cash Flow | -22.9 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||||
| Net Income | (60.6) | (25.0) | (27.1) | (30.0) | (25.4) | (23.0) | (24.4) | (15.8) | (14.4) | (10.2) | (17.6) | (20.4) | (13.2) | 2.1 |
| Depreciation & Amortization | 1.4 | 0.7 | 0.7 | 0.9 | 0.9 | 0.5 | 0.5 | 0.5 | 0.4 | 0.2 | 0.3 | 0.4 | 0.4 | 0.5 |
| Deferred Income Tax | (2.8) | 0 | 1.8 | 5.7 | (4.2) | 0 | (0.3) | (0.3) | (1.3) | (3.4) | (0.6) | (1.7) | 12.7 | 2.2 |
| Stock Based Compensation | 2.3 | 2.2 | 1.5 | 1.3 | 1.8 | 2.5 | 1.5 | 1.1 | 1.2 | 1.0 | 0.9 | 0.8 | 1.0 | 1.8 |
| Other Operating Activities | 21.9 | (5.4) | 39 K | 0.2 | 72 K | (2.6) | (0.5) | (0.4) | (0.2) | (2.3) | 0.4 | 0.7 | (13.6) | 0.4 |
| Change in Working Capital | 15.2 | 1.2 | (0.5) | (1.3) | 4.3 | (1.7) | 2.6 | 0.4 | 0.2 | 0.2 | (3.6) | 48.4 K | 1.4 | 4.4 |
| Cash From Operations | (22.6) | (26.2) | (23.6) | (23.2) | (22.7) | (24.2) | (20.5) | (14.5) | (14.2) | (14.5) | (20.2) | (20.1) | (11.2) | 11.5 |
| INVESTING CASH FLOW | ||||||||||||||
| Capital Expenditures | (0.3) | (0.3) | 97 K | 0 | 73 K | (10.2) | (4.2) | 55 K | (2.7) | (0.2) | (0.1) | (0.2) | (0.3) | (0.7) |
| Other Items | 1.7 | 4.3 | (38.1) | 16.7 | 5.3 | 19.8 | (11.7) | 9.4 | (12.9) | (18.0) | (5.6) | 13.9 | (9.6) | (7.7) |
| Cash From Investing Activities | 1.4 | 4.0 | (38.2) | 16.7 | 5.3 | 9.6 | (15.9) | 9.3 | (15.6) | (18.2) | (5.7) | 13.7 | (9.9) | (8.3) |
| FINANCING CASH FLOW | ||||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (2.0) | 6.1 | (3.6) | (3.4) | (1.1) | 9.2 | 93 K | 93 K | 0.4 | 0 | 37 K | 77.8 K | 80.9 K | 0.2 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.0 | 5 K | 10.9 | 2.0 | 1 K | 3.9 | 0 | 0 | 0 | (2.4) | 3 K | (0.5) | 4.87 K | 17.6 K |
| Cash From Financing Activities | 15.1 | 20.4 | 57.7 | 17.9 | 19.2 | 13.1 | 38.7 | 2.1 | 29.5 | 30.3 | 15.8 | 15.8 | 80.7 K | 0.2 |
| CHANGE IN CASH | ||||||||||||||
| Net Change In Cash | (6.3) | (2.4) | (3.8) | 11.5 | 1.9 | (1.7) | 2.6 | (3.1) | (0.2) | (2.1) | (10.8) | 9.4 | (20.7) | 1.7 |
| FREE CASH FLOW | ||||||||||||||
| Free Cash Flow | (22.9) | (26.6) | (23.7) | (23.2) | (22.7) | (34.4) | (24.8) | (14.6) | (16.9) | (14.7) | (20.4) | (20.3) | (11.5) | 10.8 |